Adoptive Immunotherapy Using PRAME-Specific T Cells in Medulloblastoma.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Cancer Research

• Publication date

  2018-06-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-17-3140PMID 29615432
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Childhood Medulloblastoma.

  2020cited by this paper
• Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?

  2019cited by this paper
• Immunotherapy for pediatric brain tumors: past and present.

  2019cited by this paper
• Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape.

  2019cited by this paper
• Advances in Engineering Cells for Cancer Immunotherapy

  2019cited by this paper
• Medulloblastoma in the Molecular Era

  2018cited by this paper
• Enhancer profiling identifies critical cancer genes and characterizes cell identity in adult T-cell leukemia.

  2017cited by this paper
• Radiation‐induced decrease of CD8 + dendritic cells contributes to Th1/Th2 shift

  2017cited by this paper
• Alpha Particle Enhanced Blood Brain/Tumor Barrier Permeabilization in Glioblastomas Using Integrin Alpha-v Beta-3–Targeted Liposomes

  2017cited by this paper
• PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma

  2017cited by this paper
• HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial

  2017cited by this paper
• CD8+ T cell programming by cytomegalovirus vectors: applications in prophylactic and therapeutic vaccination.

  2017cited by this paper
• Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade.

  2017cited by this paper
• [Immunotherapy in brain tumors].

  2017cited by this paper
• The whole-genome landscape of medulloblastoma subtypes

  2017cited by this paper
• Preconditioning Vaccine Sites for mRNA-Transfected Dendritic Cell Therapy and Antitumor Efficacy.

  2016cited by this paper
• Oncolytic viruses as immunotherapy: progress and remaining challenges

  2016cited by this paper
• Metastatic Group 3 Medulloblastoma in a Patient With Tuberous Sclerosis Complex: Case Description and Molecular Characterization of the Tumor

  2016cited by this paper
• Serial Activation of the Inducible Caspase 9 Safety Switch After Human Stem Cell Transplantation.

  2016cited by this paper
• Beyond CTLA-4 and PD-1: Orphan nuclear receptor NR2F6 as T cell signaling switch and emerging target in cancer immunotherapy.

  2016cited by this paper
• The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

  2016cited by this paper
• Optimizing mouse models for precision cancer prevention

  2016cited by this paper
• Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid

  2016cited by this paper
• Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy

  2016cited by this paper
• Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses

  2016cited by this paper
• Immunogenic Apoptotic Cell Death and Anticancer Immunity.

  2016cited by this paper
• Preferentially Expressed Antigen in Melanoma (PRAME) and the PRAME Family of Leucine-Rich Repeat Proteins.

  2016cited by this paper
• Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study

  2016cited by this paper
• Behavioural and neurological symptoms accompanied by cellular neuroinflammation in IL-10-deficient mice infected with Plasmodium chabaudi

  2016cited by this paper
• Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non–Small Cell Lung Cancer: A Phase I Dose Escalation Study

  2016cited by this paper
• Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.

  2016cited by this paper
• PRAME is critical for breast cancer growth and metastasis.

  2016cited by this paper
• PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma

  2016cited by this paper
• Oncolytic viruses: a new class of immunotherapy drugs

  2015cited by this paper
• Skin cancer: T-VEC oncolytic viral therapy shows promise in melanoma

  2015cited by this paper
• Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

  2015cited by this paper
• Mutant MHC class II epitopes drive therapeutic immune responses to cancer

  2015cited by this paper
• Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy

  2015cited by this paper
• CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012

  2015cited by this paper
• Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma.

  2015cited by this paper
• Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation.

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Characterization of medulloblastoma in Fanconi Anemia: a novel mutation in the BRCA2 gene and SHH molecular subgroup

  2015cited by this paper
• Faculty Opinions recommendation of Structural and functional features of central nervous system lymphatic vessels.

  2015cited by this paper
• Toward understanding and exploiting tumor heterogeneity

  2015cited by this paper
• Cancer‐testis antigens PRAME and NY‐ESO‐1 correlate with tumour grade and poor prognosis in myxoid liposarcoma

  2015cited by this paper
• Different pediatric brain tumors are associated with different gene expression profiling.

  2015cited by this paper
• The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and Autoimmunity

  2015cited by this paper
• International Society of Neuropathology‐Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading

  2014cited by this paper
• Gli1/DNA interaction is a druggable target for Hedgehog-dependent tumors

  2014cited by this paper
• Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations

  2014cited by this paper
• Chimeric antigen receptor T cells for sustained remissions in leukemia.

  2014cited by this paper
• Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition.

  2014cited by this paper
• Epigenetic dysregulation: a novel pathway of oncogenesis in pediatric brain tumors

  2014cited by this paper
• Management of Pediatric and Adult Patients with Medulloblastoma

  2014cited by this paper
• Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas.

  2014influential reference
• Immunopathology of Central Nervous System Tumors

  2014cited by this paper
• Gorlin syndrome (nevoid basal cell carcinoma syndrome): Update and literature review

  2014cited by this paper
• Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene.

  2014cited by this paper
• Cytogenetic prognostication within medulloblastoma subgroups.

  2014cited by this paper
• Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.

  2013cited by this paper
• Elevated PRAME expression: what does this mean for treatment of head and neck squamous cell carcinoma?

  2013cited by this paper
• Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.

  2013cited by this paper
• Myeloablative Temozolomide Enhances CD8+ T-Cell Responses to Vaccine and Is Required for Efficacy against Brain Tumors in Mice

  2013cited by this paper
• Enhancing the Efficacy of Drug-loaded Nanocarriers against Brain Tumors by Targeted Radiation Therapy

  2013cited by this paper
• Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis.

  2013cited by this paper
• Therapeutic gene modified cell based cancer vaccines.

  2013cited by this paper
• PRAME expression in head and neck cancer correlates with markers of poor prognosis and might help in selecting candidates for retinoid chemoprevention in pre-malignant lesions.

  2013cited by this paper
• Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

  2013cited by this paper
• Signatures of mutational processes in human cancer

  2013cited by this paper
• IDO Expression in Brain Tumors Increases the Recruitment of Regulatory T Cells and Negatively Impacts Survival

  2012cited by this paper
• CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.

  2012cited by this paper
• A mouse model of the most aggressive subgroup of human medulloblastoma.

  2012cited by this paper
• Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas

  2012influential reference
• Dissecting the genomic complexity underlying medulloblastoma

  2012cited by this paper
• Wound healing after radiation therapy: Review of the literature

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• EZH2-Regulated DAB2IP Is a Medulloblastoma Tumor Suppressor and a Positive Marker for Survival

  2012cited by this paper
• Coordinated regulation of myeloid cells by tumours

  2012cited by this paper
• Expression and prognostic relevance of PRAME in primary osteosarcoma.

  2012cited by this paper
• Cancer‐testis antigens expressed in osteosarcoma identified by gene microarray correlate with a poor patient prognosis

  2012cited by this paper
• Novel mutations target distinct subgroups of medulloblastoma

  2012cited by this paper
• Factors Predicting the Need for Cerebrospinal Fluid Diversion following Posterior Fossa Tumor Surgery in Children

  2012cited by this paper
• A Phase 1 Study of a Vaccine Targeting Preferentially Expressed Antigen in Melanoma and Prostate-specific Membrane Antigen in Patients With Advanced Solid Tumors

  2011cited by this paper
• Inducible apoptosis as a safety switch for adoptive cell therapy.

  2011cited by this paper
• High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells.

  2011cited by this paper
• Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples

  2011cited by this paper
• Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.

  2011cited by this paper
• T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

  2011cited by this paper
• Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups

  2011cited by this paper
• Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma.

  2011cited by this paper
• Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome.

  2011cited by this paper
• Novel strategies to improve DNA vaccine immunogenicity.

  2011cited by this paper
• PRAME gene expression profile in medulloblastoma.

  2011cited by this paper
• PRAME-Specific Allo-HLA–Restricted T Cells with Potent Antitumor Reactivity Useful for Therapeutic T-Cell Receptor Gene Transfer

  2011cited by this paper
• Medulloblastoma comprises four distinct molecular variants.

  2011cited by this paper
• Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct

  2011cited by this paper
• Integrative prognostic risk score in acute myeloid leukemia with normal karyotype.

  2011cited by this paper
• Molecular subgroups of medulloblastoma: the current consensus

  2011cited by this paper
• A majority of the cancer/testis antigens are intrinsically disordered proteins

  2011cited by this paper

• The Knowledge Connector decision support system for multiomics-based precision oncology

  2026cites this paper
• Targeting the C/EBPβ-PRAME-EZH2 complex modulates the Netrin-4/AKT axis to inhibit renal cancer tumorigenesis and metastasis.

  2026cites this paper
• Knowledge Connector: Decision support system for multiomics-based precision oncology

  2025cites this paper
• The T cell receptor landscape of childhood brain tumors.

  2025cites this paper
• Deep Exploration of the Immunopeptidome of a Pancreatic Cancer Cell Line: Implications for Clinical Immunopeptidomics and Immunotherapy

  2025cites this paper
• Truncated form of human CD19 antigen as a suicide gene to control T-cell alloreactivity: ∆CD19

  2025cites this paper
• The Relationship of PRAME Expression with Clinicopathologic Parameters and Immunologic Markers in Melanomas: In Silico Analysis

  2025cites this paper
• Multi-omics analyses reveal biological and clinical insights in recurrent stage I non-small cell lung cancer

  2025cites this paper
• Clinicopathological and molecular landscape of 5-year IDH-wild-type glioblastoma survivors: A multicentric retrospective study.

  2024cites this paper
• Roles and interactions of tumor microenvironment components in medulloblastoma with implications for novel therapeutics

  2024cites this paper
• Self-sufficient primary natural killer cells engineered to express T cell receptors and interleukin-15 exhibit improved effector function and persistence.

  2024cites this paper
• Immunohistochemical Expression and Significance of Preferentially Expressed Antigen in Melanoma (PRAME) in Gynecological Tumors: A Single-institution Retrospective Analysis

  2024cites this paper
• GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma

  2024cites this paper
• CAR T-cells to treat brain tumors.

  2023cites this paper
• Molecular and clinicopathological implications of PRAME expression in adult glioma

  2023cites this paper
• Characterisation of the protein expression of the emerging immunotherapy targets VISTA, LAG-3 and PRAME in primary uveal melanoma: insights from a southern French patient cohort.

  2023cites this paper
• Medulloblastoma targeted therapy: From signaling pathways heterogeneity and current treatment dilemma to the recent advances in development of therapeutic strategies.

  2023cites this paper
• Transcriptomic insights into adenoid cystic carcinoma via RNA sequencing

  2023cites this paper
• Preferentially Expressed Antigen in Melanoma Is a Multifaceted Cancer Testis Antigen with Diverse Roles as a Biomarker and Therapeutic Target

  2023cites this paper
• Human iPSC-derived preclinical models to identify toxicity of tumor-specific T cells with clinical potential

  2023cites this paper
• Target Selection for T-Cell Therapy in Epithelial Ovarian Cancer: Systematic Prioritization of Self-Antigens

  2023cites this paper
• PRAME Expression: A Target for Cancer Immunotherapy and a Prognostic Factor in Uveal Melanoma

  2023cites this paper
• Transcriptome Analysis of Diffuse Large B-Cell Lymphoma Cells Inducibly Expressing MyD88 L265P Mutation Identifies Upregulated CD44, LGALS3, NFKBIZ, and BATF as Downstream Targets of Oncogenic NF-κB Signaling

  2023cites this paper
• Next‐generation chimeric antigen receptors for T‐ and natural killer‐cell therapies against cancer

  2023cites this paper
• Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies

  2023cites this paper
• Paving the Way to Solid Tumors: Challenges and Strategies for Adoptively Transferred Transgenic T Cells in the Tumor Microenvironment

  2022cites this paper
• WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma

  2022cites this paper
• Nanomedicines and cell-based therapies for embryonal tumors of the nervous system.

  2022cites this paper
• Multidisciplinary Management of Medulloblastoma: Consensus, Challenges, and Controversies.

  2022cites this paper
• PRAME Expression in Endometrioid and Serous Endometrial Carcinoma: A Potential Immunotherapeutic Target and Possible Diagnostic Pitfall

  2022cites this paper
• PRAME protein expression in DICER1‐related tumours

  2022cites this paper
• MEDULLOBLASTOMA: IMMUNE MICROENVIRONMENT AND TARGETED NANO-THERAPY

  2022cites this paper
• The Current Landscape of Targeted Clinical Trials in Non-WNT/Non-SHH Medulloblastoma

  2022cites this paper
• Cellular immunotherapy for medulloblastoma

  2022cites this paper
• Hedgehog Pathway Inhibitors against Tumor Microenvironment

  2021cites this paper
• Biology in Practice: Harnessing the Curative Potential of the Immune System in Lymphoid Cancers.

  2021cites this paper
• New Era of Immunotherapy in Pediatric Brain Tumors: Chimeric Antigen Receptor T-Cell Therapy

  2021cites this paper
• Development of a New Highly Selective Monoclonal Antibody against Preferentially Expressed Antigen in Melanoma (PRAME) and Identification of the Target Epitope by Bio-Layer Interferometry

  2021cites this paper
• Advances in immunotherapeutic targets for childhood cancers: a focus on glypican-2 and B7-H3.

  2021cites this paper
• Prognostic implications of immune-related eight-gene signature in pediatric brain tumors

  2021cites this paper
• Innovative and Promising Strategies to Enhance Effectiveness of Immunotherapy for CNS Tumors: Where Are We?

  2021influential citation
• Biological Role of MYCN in Medulloblastoma: Novel Therapeutic Opportunities and Challenges Ahead

  2021cites this paper
• Strategy to prevent epitope masking in CAR.CD19+ B-cell leukemia blasts

  2021cites this paper
• Targeting cancer stem cells in medulloblastoma by inhibiting AMBRA1 dual function in autophagy and STAT3 signalling

  2021cites this paper
• Immunosuppression in Medulloblastoma: Insights into Cancer Immunity and Immunotherapy

  2021cites this paper
• Immune cell landscape and immunotherapy of medulloblastoma

  2021cites this paper
• Depletion of T cells via Inducible Caspase 9 Increases Safety of Adoptive T-Cell Therapy Against Chronic Hepatitis B

  2021cites this paper
• Cell Therapy for Uveal Melanoma

  2021cites this paper
• Immunotherapy in Medulloblastoma: Current State of Research, Challenges, and Future Perspectives

  2021cites this paper
• Sperm protein 17 targeting for epithelialovarian cancer treatment in the eraof modern immunoengineering

  2021cites this paper
• Engineered T-cell Receptor T Cells for Cancer Immunotherapy

  2021cites this paper
• The Growing Relevance of Immunoregulation in Pediatric Brain Tumors

  2021cites this paper
• LACE: Inference of cancer evolution models from longitudinal single-cell sequencing data

  2021cites this paper
• Immunotherapy for Medulloblastoma: Current Perspectives

  2020cites this paper
• Longitudinal cancer evolution from single cells

  2020cites this paper
• Clinicopathological and Prognostic Significance of PRAME Overexpression in Human Cancer: A Meta-Analysis

  2020cites this paper
• Development of a prognostic model based on an immunogenomic landscape analysis of medulloblastoma

  2020cites this paper
• Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma

  2020cites this paper
• CAR T Cell Therapy for Pediatric Brain Tumors

  2020cites this paper
• Update on Pediatric Brain Tumors: the Molecular Era and Neuro-immunologic Beginnings

  2020cites this paper
• The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer

  2020cites this paper
• Circulating miR34a levels as a potential biomarker in the follow-up of Ewing sarcoma

  2020cites this paper
• CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T cells

  2020cites this paper
• Principles of tumorigenesis and emerging molecular drivers of SHH‐activated medulloblastomas

  2019cites this paper
• Adoptive Immunotherapy and Cellular Therapy

  2019cites this paper
• Medulloblastoma

  2019cites this paper
• Immunotherapy for pediatric brain tumors: past and present.

  2019cites this paper
• Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy.

  2019cites this paper
• Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?

  2019cites this paper
• Endoscopic ultrasound may be used to deliver gene expression signatures using digital mRNA detection methods to immunophenotype pancreatic ductal adenocarcinoma to facilitate personalized immunotherapy.

  2019cites this paper
• Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia

  2019cites this paper
• Advances in Engineering Cells for Cancer Immunotherapy

  2019cites this paper
• CD24 and PRAME Are Novel Grading and Prognostic Indicators for Pineal Parenchymal Tumors of Intermediate Differentiation

  2019cites this paper
• PRAME and HLA Class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy

  2018cites this paper
• Neutralization of IFN γ improves the safety pro�le of CAR T-cells while maintaining unaffected e�cacy against B-cell malignancies

  year unknowncites this paper
• Self-suf fi cient primary natural killer cells engineered to express T cell receptors and interleukin-15 exhibit improved effector function and persistence

  year unknowncites this paper